[go: up one dir, main page]

AR027066A1 - Forma de dosificacion de farmaco en capas impulsada por hidrogel - Google Patents

Forma de dosificacion de farmaco en capas impulsada por hidrogel

Info

Publication number
AR027066A1
AR027066A1 ARP000106853A ARP000106853A AR027066A1 AR 027066 A1 AR027066 A1 AR 027066A1 AR P000106853 A ARP000106853 A AR P000106853A AR P000106853 A ARP000106853 A AR P000106853A AR 027066 A1 AR027066 A1 AR 027066A1
Authority
AR
Argentina
Prior art keywords
dosage form
hour
weight
environment
sertraline
Prior art date
Application number
ARP000106853A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR027066A1 publication Critical patent/AR027066A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma de dosificacion de liberacion controlada para sertralina tiene un nucleo que comprende una composicion que contiene sertralina y una composicionhinchable en agua, en donde la composicion hinchable en agua está situada en una region separada dentro del nucleo. Un revestimiento en torno al nucleo espermeable al agua, insoluble en agua, y tiene al menos una abertura de suministro a través del mismo. En una realizacion, la forma de dosificacion liberasertralina hacia el entorno de uso con una velocidad media de 6 a 10% en peso por hora desde la segunda hasta la décima hora después de la introduccion en unentorno de uso, y menos de aproximadamente 25% en peso durante las dos primeras horas y al menos 70% en peso al cabo de la décima ho ra, en donde losporcentajes corresponden a la masa de fármaco liberado desde el comprimido dividida por la masa total de fármaco originalmente presente en el comprimido. Enotra realizacion, la forma de dosificacion libera menos de aproximadamente 25% en peso de sertralina hacia el entorno de uso al cabo de la segunda hora despuésde la introduccion de la forma de dosificacion en el entorno de uso, y suministra al menos 25% en peso desde la octava hora hasta la vigesimocuarta.
ARP000106853A 1999-12-23 2000-12-21 Forma de dosificacion de farmaco en capas impulsada por hidrogel AR027066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17210899P 1999-12-23 1999-12-23

Publications (1)

Publication Number Publication Date
AR027066A1 true AR027066A1 (es) 2003-03-12

Family

ID=22626396

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106853A AR027066A1 (es) 1999-12-23 2000-12-21 Forma de dosificacion de farmaco en capas impulsada por hidrogel

Country Status (15)

Country Link
US (1) US6899896B2 (es)
EP (1) EP1239839A2 (es)
JP (1) JP2003518487A (es)
AR (1) AR027066A1 (es)
AU (1) AU1724301A (es)
BR (1) BR0016707A (es)
CA (1) CA2395231C (es)
CO (1) CO5271728A1 (es)
GT (1) GT200000220A (es)
MX (1) MXPA02006335A (es)
PA (1) PA8508901A1 (es)
PE (1) PE20010983A1 (es)
TN (1) TNSN00251A1 (es)
UY (1) UY26493A1 (es)
WO (1) WO2001047498A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022046A3 (cs) * 1999-12-23 2002-11-13 Pfizer Products Inc. Hydrogelem hnaná dávková forma účinné sloľky
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
US20030170309A1 (en) * 2001-06-22 2003-09-11 Babcock Walter C. Pharmaceutical compositions containing polymer and drug assemblies
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
CN1596104A (zh) * 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 改进的释放剂型
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
CN100544717C (zh) * 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040081695A1 (en) * 2002-09-28 2004-04-29 Sowden Harry S Dosage forms having an inner core and an outer shell
WO2004041773A1 (en) * 2002-11-07 2004-05-21 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
CA2565159A1 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US20060239956A1 (en) * 2005-04-26 2006-10-26 Lulu Henson Preparation and use of hydrogels
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
WO2007057762A2 (en) * 2005-11-16 2007-05-24 Pfizer Limited Osmotic bi-layer tablet
CN100563637C (zh) * 2006-10-13 2009-12-02 北京红林制药有限公司 一种控释给药的药芯组合物和控释制剂及其制备方法
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EP2506842B1 (en) * 2009-12-04 2015-01-21 Sunovion Pharmaceuticals Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof
WO2011078993A1 (en) 2009-12-21 2011-06-30 Aptapharma, Inc. Functionally-coated multilayer tablets
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
JP6455293B2 (ja) * 2015-04-21 2019-01-23 ニプロ株式会社 セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5366738A (en) 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
USRE33994E (en) 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4865598A (en) 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
GB8521494D0 (en) 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4755180A (en) 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
ES2039287T3 (es) 1987-01-14 1993-09-16 Ciba-Geigy Ag Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles.
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4946687A (en) 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4971998A (en) 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4837111A (en) 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
FI101344B1 (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US5030456A (en) 1988-11-07 1991-07-09 Alza Corporation Dosage form for treating cardiovascular diseases
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
DD295760A5 (de) 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5019396A (en) 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5273752A (en) 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5126142A (en) 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5130338A (en) 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US5091190A (en) 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5035897A (en) 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5200197A (en) 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5178866A (en) 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5057321A (en) 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
DK0550641T3 (da) 1990-09-28 1994-08-22 Pfizer Dispenseringsanordning indeholdende et hydrofobt medium
US5284662A (en) 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5208037A (en) 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
EP0607321A1 (en) 1991-10-10 1994-07-27 Alza Corporation Osmotic drug delivery devices with hydrophobic wall materials
US5183942A (en) 1991-11-05 1993-02-02 The Scripps Research Institute Ten-membered ring enediynediols and enediynediones having DNA cleaving properties
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5294770A (en) 1992-01-14 1994-03-15 Alza Corporation Laser tablet treatment system with dual access to tablet
US5246711A (en) 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating dysthymia
US5688518A (en) 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5246710A (en) 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating cyclothymia
US5185158A (en) 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
ES2149250T3 (es) 1993-04-23 2000-11-01 Novartis Ag Dispositivo para la administracion de medicamentos con liberacion controlada.
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
HU213407B (en) 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
MX9605419A (es) 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
US5698224A (en) 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5529787A (en) 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5718700A (en) 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5658474A (en) 1994-12-16 1997-08-19 Alza Corporation Method and apparatus for forming dispenser delivery ports
US5607696A (en) 1995-02-10 1997-03-04 Alza Corporation Osmotic membrane and delivery device
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
BRPI9802144B1 (pt) 1997-05-30 2017-03-28 Ezequiel Mayorga Jorge dispositivo osmótico multicapa aperfeiçoado
US6517866B1 (en) * 1997-07-01 2003-02-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs

Also Published As

Publication number Publication date
UY26493A1 (es) 2001-07-31
JP2003518487A (ja) 2003-06-10
EP1239839A2 (en) 2002-09-18
CA2395231C (en) 2006-08-15
CO5271728A1 (es) 2003-04-30
WO2001047498A2 (en) 2001-07-05
PE20010983A1 (es) 2001-10-01
AU1724301A (en) 2001-07-09
MXPA02006335A (es) 2002-12-13
PA8508901A1 (es) 2003-12-10
BR0016707A (pt) 2002-09-03
CA2395231A1 (en) 2001-07-05
TNSN00251A1 (fr) 2002-05-30
GT200000220A (es) 2002-06-14
US20010044474A1 (en) 2001-11-22
WO2001047498A3 (en) 2001-11-15
US6899896B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
AR027066A1 (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
ECSP034455A (es) Forma de dosificacion de farmaco activada por hidrogel
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
AR022254A1 (es) Composicion de administracion oral.
PE12991A1 (es) Composicion dentifrica oral antiplaca antibacterial
ES2038181T3 (es) Composiciones farmaceuticas de liberacion sostenida en forma de dosificacion oral.
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
ES2157944T3 (es) Nucleos de pastillas de liberacion inmediata de medicamentos insolubles que poseen un recubrimiento de liberacion sostenida.
ES2050363T3 (es) Sistema para la liberacion intraoral de medicamento.
CO5280073A1 (es) Composiciones
UY25544A1 (es) Forma de dosificación de nefazodona
BR0007360A (pt) Composição de liberação controlada
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
ES2191987T3 (es) Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
CA2306214A1 (en) Plaster for topical use containing heparin and diclofenac
YU36401A (sh) Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem
ES509179A0 (es) "un metodo de fabricacion de una composicion farmaceutica de liberacion retardada en forma de pastillas que contiene como agente terapeutico ibuprofen o flurbiprofen".
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
ES2142430T3 (es) Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral.
AR016350A1 (es) Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos
ES2058977T3 (es) Preparado absorbible por via percutanea a base de eperisona o tolperisona.
ECSP003853A (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure